-
10 questions to clarify the management strategy of "type 2 diabetes combined with cardiovascular disease" World Diabetes Day
Time of Update: 2023-01-06
Sixth, the choice of antihypertensive drugs: it is not recommended to combine ACE inhibitors and ARBs The five commonly used antihypertensive drugs are ACEI, ARB, calcium channel blockers, diuretics and selective β receptor blockers, all of which can be used in diabetic patients and angiotensin receptor neprilyprilysin inhibitors (ARNIs) with newly indicated indications for hypertension.
-
10 questions to clarify the management strategy of "type 2 diabetes combined with cardiovascular disease" World Diabetes Day
Time of Update: 2023-01-06
Sixth, the choice of antihypertensive drugs: it is not recommended to combine ACE inhibitors and ARBs The five commonly used antihypertensive drugs are ACEI, ARB, calcium channel blockers, diuretics and selective β receptor blockers, all of which can be used in diabetic patients and angiotensin receptor neprilyprilysin inhibitors (ARNIs) with newly indicated indications for hypertension.
-
How does the gut help drive COVID-19
Time of Update: 2022-09-07
"Single-cell gene expression links SARS-CoV-2 infection and gut serotonin New findings from Flinders University demonstrate the molecular link between COVID-19 and serotonergic cells in the gut .
-
Application of Multispectral Fluorescence Imaging Based on Chlorophyll Fluorescence and Chemometrics in the Study of Seed Vitality
Time of Update: 2022-08-30
The high fluorescence values coincided with low-quality seed batches (Fig. 2), and could be better when 620/730 nm (Fig. 2G) and 660/700 nm (Fig. 2B) were used for chlorophyll excitation in tomato and carrot seeds, respectively distinguish them .
-
Southeastern China case-control study: How do common dietary perchlorate and iodine affect our thyroid
Time of Update: 2022-01-23
The aim of this study was to investigate the effect of perchlorate and iodine on the risk of nodular goiter (NG), papillary thyroid microcarcinoma (PTMC) and PTC and to explore their association with thyroid function markers to identify thyroid disease key risk factors .
-
Hengrui received clinical approval for many new drugs
Time of Update: 2021-12-03
On November 26, Hengrui issued an announcement that two clinical trial applications were approved by the National Food and Drug Administration: Carrelizumab combined with famitinib malate and paclitaxel for injection (albumin-bound) for the treatment of patients with advanced solid tumors An open, multi-center phase Ib/II clinical study; SHR-1701 injection combined with lenvatinib mesylate capsules vs.
-
"Chinese Multidisciplinary Diagnosis and Treatment Guidelines for Cerebral Hemorrhage Related to Blood Coagulation Dysfunction" is released
Time of Update: 2021-11-05
01 Emergency treatment and evaluation of coagulation function (1) If the patient is found to be HDICH in the pre-hospital emergency, the specific name of the medication should be clarified, and the antiplatelet or anticoagulant drugs should be stopped immediately (level I recommendation, level C evidence) .
-
Int J Urol: The impact of platinum-based first-line chemotherapy on the overall survival of patients with metastatic urothelial carcinoma
Time of Update: 2021-11-02
Recently, researchers from Japan published an article in Int J Urol, investigating the effect of the number of cycles of chemotherapy and the objective response on the overall survival of patients with metastatic urinary tract cancer treated with pembrolizumab .
-
Trypsin Inhibitor
Time of Update: 2021-03-10
Among the many factors that have been implicated as having an adverse effect on the nutritional value of proteins is a class of proteins, known as protease inhibitors, that has the ability to inhibit
-
The Lancet: New treatment for multiple myeloma increases lifetime by 47
Time of Update: 2021-02-24
So far, Selinexor has been approved for two tumor adaptations in the U.S.: Last July, Selinexor was approved by the U.S. FDA to treat adult recurring/refractic multiple myeloma patients who have previously received at least four treatments, including at least two protease inhibitors, at least two immunomodulants, and anti-CD38 monoclonal antibodies.
-
The FDA's committee of experts has asked the DEP-4 sugar-lowering drug to update safety information
Time of Update: 2021-02-03
The FDA's committee of experts met Tuesday to discuss long-term safety data for AstraZeneta's diabetes drug Ongliza and Takeda's diabetes drug Nesina.
AstraZeneta Ongliza, Takeda Nesina and Nanuvia of Mercedon are among the DPP-4 inhibitors, whose long-term safety data are expected to be released in June.
-
Nature: Severe new crown patients may be closely related to five genes
Time of Update: 2020-12-22
BEIJING, Dec. 14 (Reporter Hu Dingkun Zhang Mengran) Recently, an international team of researchers from the University of Edinburgh, Oxford University, Cambridge University, Dublin University in Ireland, Zhongshan University in China, West Lake University and other institutions in the journal Nature said that patients with severe new coronary pneumonia or closely related to five key genes, this discovery provides important clues for the screening of new coronary drugs.
-
Nat Med: Combined PD-1, BRAF and MEK inhibitors to treat advanced BRAF mutant melanoma
Time of Update: 2020-10-13
In Part 1, the recommended phase 3 was determined based on the rate of dose-restricted toxicity (DLTs; primary endpoint): 400mg Spartali pearl monoanti plus 150mg dabrafini every 4 weeks, plus 2mg qumentinib twice a day.
-
Hypertension: Relationship between renin-angiotensin-aldosterone system inhibitors and the risk of SARS-CoV-2 infection
Time of Update: 2020-09-20
, the study found for the first time that taking ARB increased the risk of SARS-CoV-2 infection in younger patients compared to ACEI, with no significant effect on COVID-19 outcomes.
-
Noscheng Kinhua Pan FGFR Inhibitor Phase 2 clinical completion of the first patient in-group
Time of Update: 2020-07-24
From: The medical mission recently, Nocheng Jianhua announced that it has completed the first case of patient admission in the second phase of clinical study on the treatment of urinary skin cancer i
